在阿尔茨海默氏病中,RTP801与tRNA结合酶复合体相互作用,并对其RNA结合酶活性进行失调
Genís Campoy-Campos1,2, Julia Solana-Balaguer1,2, Anna Guisado-Corcoll1,2,3
1Departament de Biomedicina, Institut de Neurociències, Universitat de Barcelona, Barcelona 08036, Catalonia, Spain.
Nucleic acids research
|September 13, 2024
概括
升高的RTP801/REDD1蛋白质会损害阿尔茨海默病 (AD) 中的RNA处理. 沉默RTP801恢复RNA处理并防止神经元异常,这表明RTP801抑制是潜在的AD疗法.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- RTP801/REDD1是一种应激反应蛋白,与阿尔茨海默氏症 (AD) 等神经退行性疾病有关.
- RTP801有助于AD的认知缺陷和神经炎症.
- 展开的蛋白质反应 (UPR) 涉及tRNA结合酶复合体 (tRNA-LC) 的RNA处理.
研究的目的:
- 研究RTP801与tRNA结合酶复合体 (tRNA-LC) 之间的相互作用.
- 确定RTP801在RNA处理中的作用,特别是XBP1剪接,在AD的背景下.
- 评估在AD中准RTP801的治疗潜力.
主要方法:
- 研究了RTP801与tRNA-LC组件的相互作用 (HSPC117,DDX1,CGI-99).
- 评估了RTP801对XBP1剪接在体外和人类AD死后样本中的影响.
- 利用AD的5xFAD小鼠模型研究RTP801对RNA处理和神经元形态的沉默效应.
主要成果:
- RTP801与HSPC117,DDX1和CGI-99相互作用,它们是tRNA-LC的成员.
- RTP801的淘汰促进了XBP1的拼接,而RTP801的过度表达则抑制了它.
- 在AD样本中RTP801升高与XBP1拼接减少相关;在5xFAD小鼠中RTP801沉默恢复了XBP1拼接,并防止了异常tRNA积累和树突缺陷.
结论:
- RTP801损害了RNA处理,包括XBP1剪接和tRNA结合,在体外和体内.
- 由于RTP801升高而导致的功能失调的RNA处理有助于AD的发病.
- 抑制RTP801代表了阿尔茨海默病的有希望的治疗策略.
相关概念视频
Enzyme-linked Receptors
77.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.6K
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
tRNA Activation
19.1K
Aminoacyl-tRNA synthetases are present in both eukaryotes and bacteria. Though eukaryotes have 20 different aminoacyl-tRNA synthetases to couple to 20 amino acids, many bacteria do not have genes for all of these aminoacyl-tRNA synthetases. Despite this, they still use all 20 amino acids to synthesize their proteins. For instance, some bacteria do not have the gene encoding the enzyme that couples glutamine with its partner tRNA. In these organisms, one enzyme adds glutamic acid to all of the...
19.1K
Transfer RNA Synthesis
11.9K
One of the unique features of tRNA is the presence of modified bases. In some tRNAs, modified bases account for nearly 20% of the total bases in the molecule. Altogether, these unusual bases protect the tRNA from enzymatic degradation by RNases.
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
Each of these chemical modifications is carried by a specific enzyme, post-transcription. All of these enzymes have unique base and site-specificity. Methylation, the most common chemical modification, is carried by at least nine different enzymes, with...
11.9K


